Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2024)
Historic Total Non-Current Liabilities for Silence Therapeutics (SLN) over the last 6 years, with Q3 2024 value amounting to -$75.3 million.
- Silence Therapeutics' Total Non-Current Liabilities rose 80.05% to -$75.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$75.3 million, marking a year-over-year increase of 80.05%. This contributed to the annual value of -$73.2 million for FY2023, which is 19320.61% down from last year.
- As of Q3 2024, Silence Therapeutics' Total Non-Current Liabilities stood at -$75.3 million, which was up 80.05% from -$73.4 million recorded in Q2 2024.
- In the past 5 years, Silence Therapeutics' Total Non-Current Liabilities ranged from a high of $97.7 million in Q4 2021 and a low of -$90.0 million during Q1 2022
- In the last 5 years, Silence Therapeutics' Total Non-Current Liabilities had a median value of -$75.3 million in 2022 and averaged -$48.5 million.
- Per our database at Business Quant, Silence Therapeutics' Total Non-Current Liabilities soared by 23982.31% in 2020 and then tumbled by 19834.59% in 2023.
- Silence Therapeutics' Total Non-Current Liabilities (Quarter) stood at $67.8 million in 2020, then soared by 44.17% to $97.7 million in 2021, then decreased by 23.81% to $74.5 million in 2022, then plummeted by 198.35% to -$73.2 million in 2023, then decreased by 2.83% to -$75.3 million in 2024.
- Its last three reported values are -$75.3 million in Q3 2024, -$73.4 million for Q2 2024, and -$71.4 million during Q1 2024.